Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Stemline Therapeutic (STML)

Stemline Therapeutic (STML)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 670,329
  • Shares Outstanding, K 43,956
  • Annual Sales, $ 500 K
  • Annual Income, $ -85,020 K
  • 60-Month Beta 1.29
  • Price/Sales 1,268.57
  • Price/Cash Flow N/A
  • Price/Book 6.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.40
  • Number of Estimates 6
  • High Estimate -0.31
  • Low Estimate -0.53
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +45.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.75 +19.61%
on 07/17/19
18.22 -16.30%
on 08/08/19
+2.25 (+17.31%)
since 07/16/19
3-Month
12.54 +21.61%
on 07/15/19
18.22 -16.30%
on 08/08/19
+0.63 (+4.31%)
since 05/16/19
52-Week
7.82 +95.01%
on 12/21/18
18.22 -16.30%
on 08/08/19
+0.10 (+0.66%)
since 08/16/18

Most Recent Stories

More News
Global Baculoviral IAP Repeat Containing Protein 5 Market Insights, Forecast to 2019 Analysis by Application, Size, Production, Market Share, Consumption, Trends and Forecast 2025

The market size of Baculoviral IAP Repeat Containing Protein 5 is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million...

IMV.TO : 4.07 (+9.70%)
STML : 15.25 (+5.68%)
Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein,...

STML : 15.25 (+5.68%)
Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced...

JPM : 107.72 (+2.40%)
STML : 15.25 (+5.68%)
Stemline Therapeutics Announces Proposed Public Offering of Common Stock

Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial -stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced...

JPM : 107.72 (+2.40%)
STML : 15.25 (+5.68%)
Stemline Therape is Among the Companies in the Biotechnology Industry with the Best Relative Performance (STML , AMAG , RDUS , FLXN , RARE )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

RDUS : 23.12 (+2.53%)
STML : 15.25 (+5.68%)
AMAG : 11.40 (unch)
Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS(R)

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the Centers...

STML : 15.25 (+5.68%)
Stemline Therape is Among the Companies in the Biotechnology Industry with the Best Relative Performance (STML , CHRS , CLVS , MNTA , EBS )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

STML : 15.25 (+5.68%)
CHRS : 18.88 (+2.00%)
CLVS : 5.60 (+7.69%)
Stemline Therapeutics (STML) Reports Q2 Loss, Tops Revenue Estimates

Stemline Therapeutics (STML) delivered earnings and revenue surprises of 10.64% and 47.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

STML : 15.25 (+5.68%)
Stemline Therapeutics: 2Q Earnings Snapshot

NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Friday reported a loss of $16.8 million in its second quarter.

STML : 15.25 (+5.68%)
Stemline Therapeutics Reports Second Quarter 2019 Financial Results

-- Net revenue for ELZONRIS(R) was $13.0 million for the second quarter

STML : 15.25 (+5.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade STML with:

Business Summary

Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric...

See More

Key Turning Points

2nd Resistance Point 15.98
1st Resistance Point 15.61
Last Price 15.25
1st Support Level 14.66
2nd Support Level 14.08

See More

52-Week High 18.22
Last Price 15.25
Fibonacci 61.8% 14.25
Fibonacci 50% 13.02
Fibonacci 38.2% 11.79
52-Week Low 7.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar